The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced
Abstract Background The global pandemic COVID-19 caused by the new coronavirus SARS-CoV-2 has already caused about 1.4 million deaths, and to date, there are no effective or direct antiviral vaccines. Some vaccines are in the last stages of testing. Overall mortality rates vary between countries, fo...
Main Authors: | Antonio Vitiello, Raffaele La Porta, Vilma D’Aiuto, Francesco Ferrara |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2021-01-01
|
Series: | Egyptian Liver Journal |
Subjects: | |
Online Access: | https://doi.org/10.1186/s43066-021-00082-y |
Similar Items
-
Liver and COVID-19: possible mechanisms of damage
by: Marina G. Mnatsakanyan, et al.
Published: (2021-04-01) -
Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury
by: Anca D. Petrescu, et al.
Published: (2021-07-01) -
Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
by: Ludovico Abenavoli, et al.
Published: (2018-10-01) -
Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
by: Ludovico Abenavoli, et al.
Published: (2020-06-01) -
On the Pharmacology of Farnesoid X Receptor Agonists: Give me an “A”, Like in “Acid”
by: Eva Hambruch, et al.
Published: (2016-06-01)